MORRISTOWN, N.J., June 19 /PRNewswire/ -- New health policies released yesterday by the American Medical Association (AMA) include a resolution to increase physician education about the importance of counseling patients on the appropriate use of aspirin to prevent heart disease and stroke. Notably, in the AMA's announcement release, the Association pointed to the strong evidence supporting aspirin's benefits in preventing cardiovascular (CV) events: "six trials, involving more than 95,000 adult men and women, have shown aspirin may be effective in reducing the risk of heart attack and stroke."(i)
As the makers of Bayer(R) Aspirin, we applaud the AMA for adopting this policy, which will amplify the discussion of aspirin use for appropriate patients as a proven, cost-effective strategy for preventing heart attacks and strokes, the nation's number-one and number-three killers. With its emphasis on physician counseling of patients about aspirin, the AMA resolution is an important step in helping to address the well-documented problem of aspirin underutilization in America.
Heart disease is the leading cause of death and disability in the U.S., affecting men, women and all ethnic groups. In fact, nearly 71 million people are at risk for cardiovascular disease (CVD) and, according to the American Heart Association (AHA), every 26 seconds an American will suffer a coronary event.
Aspirin's potential to reduce the burden of CVD is underscored in a Partnership For Prevention report, which ranked 25 evidence-based clinical preventive services recommended by the United States Preventive Services Task Force (USPSTF) and Advisory Committee on Immunization Practices based on these services' health impact and economic value; aspirin counseling was rated the number-one preventive health service that, if optimized, would dramatically contribute to improved public health. The report also states that 45,000 lives would be saved each year if more adults took a daily low-dose aspirin to prevent heart disease.
Aspirin is one of the most extensively studied drugs in history, with a 110-year track record of efficacy and safety. More than 200,000 patients have been studied in more than 200 randomized clinical trials evaluating aspirin efficacy and safety across a range of doses. When taken regularly, aspirin has been shown to significantly reduce the risk of heart attack and recurrent stroke. However, despite its well-established benefits, including support from guidelines recommendations by AHA, USPSTF, American Diabetes Association, World Health Organization and other health organizations, aspirin is widely underutilized in the United States and the world over. Reports show aspirin is used by only about half of those who should be using it to prevent CV events.
Bayer is committed to improving public health by promoting the safe and appropriate use of aspirin for CV event prevention. In addition to supporting numerous scientific studies in cardiovascular disease, Bayer has meaningful partnerships with many organizations, including AHA, PFP, WomenHeart: The National Coalition for Women with Heart Disease, and the National Stroke Association, to help raise awareness of the risks of CVD and ways to help control risk factors, including increasing the appropriate use of aspirin therapy.
About Bayer Consumer Care
The Consumer Care Division of Bayer HealthCare LLC, is headquartered in Morristown, N.J. Bayer's Consumer Care Division is among the largest marketers of over-the-counter medications and nutritional supplements in the world. Some of the most trusted and recognizable brands in the world today come from the Bayer portfolio of products. These include Bayer(R) Aspirin, ALEVE(R), Flanax(R)/Apronax(R), Alka-Seltzer Plus(R), Bactine(R), RID(R), Phillips'(R) Milk of Magnesia, Midol(R), Alka-Seltzer(R), Talcid(R), Rennie(R), Canesten(R), Bepanthen(R), Bepanthol(R), One A Day(R) vitamins, Flintstones(TM) vitamins, Supradyn(R), Redoxon(R), Berocca(R), Cal-D-Vita/Elevit(R), Vital 50 Plus(R), CardioAspirin(R).
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.
(i) American Medical Association. AMA adopts new policies at annual
meeting (press release). Chicago, IL, June 17, 2008.
|SOURCE Bayer Consumer Care|
Copyright©2008 PR Newswire.
All rights reserved